NovoCure Limited (NVCR) |
|
57.17 0.355 (0.62%)
|
03-24 16:00 |
|
Open: |
56.35 |
Pre. Close: |
56.815 |
|
High:
|
57.64 |
Low:
|
56.055 |
|
Volume:
|
559,125 |
Market Cap:
|
6,029(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:28:25 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 87.34  One year: 100.86 |
| Support: |
Support1: 56.05 Support2: 46.63 |
| Resistance: |
Resistance1: 74.78 Resistance2: 86.36 |
| Pivot: |
64.77 |
| Moving Average: |
MA(5): 57.52 MA(20): 67.77
MA(100): 78.98 MA(250): 77.45 |
| MACD: |
MACD(12,26): -6.9 Signal(9): -6.1 |
| Stochastic oscillator: |
%K(14,3): 2.4 %D(3): 4.2 |
| RSI: |
RSI(14): 24.5 |
| 52-week: |
High: 120.02 Low: 56.05 |
| Average Vol(K): |
3-Month: 1,048 (K) 10-Days: 855 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NVCR ] has closed above bottom band by 22.0%. Bollinger Bands are 29.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
57.71 - 57.92 |
57.92 - 58.1 |
|
Low:
|
55.48 - 55.75 |
55.75 - 55.96 |
|
Close:
|
56.76 - 57.18 |
57.18 - 57.52 |
|
Company Description |
|
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. |
Headline News |
Mon, 20 Mar 2023
NovoCure Limited (NASDAQ:NVCR) Shares Sold by Peregrine ... - MarketBeat
Sun, 19 Mar 2023
Taylor Frigon Capital Management LLC Cuts Stake in NovoCure ... - MarketBeat
Sat, 18 Mar 2023
NovoCure Limited's (NASDAQ:NVCR) latest 14% decline adds to one-year losses, institutional investors may consider drastic measures - Simply Wall St
Fri, 17 Mar 2023
What is Wall Street's Target Price for Novocure Ltd (NVCR) Stock Friday? - InvestorsObserver
Thu, 16 Mar 2023
2023-03-16 | NDAQ:NVCR | Press Release | NovoCure Limited - Stockhouse
Tue, 14 Mar 2023
Guru Fundamental Report for NVCR - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Instruments & Supplies |
| Shares Out. |
105 (M) |
| Shares Float |
104 (M) |
|
% Held by Insiders
|
1.1 (%) |
|
% Held by Institutions
|
89.8 (%) |
|
Shares Short
|
7,760 (K) |
|
Shares Short P.Month
|
7,770 (K) |
Stock Financials |
|
EPS
|
0.1 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.6 |
|
Profit Margin (%)
|
-15.1 |
|
Operating Margin (%)
|
-12.8 |
|
Return on Assets (ttm)
|
-3.8 |
|
Return on Equity (ttm)
|
-19.1 |
|
Qtrly Rev. Growth
|
-2 |
|
Gross Profit (p.s.)
|
4 |
|
Sales Per Share
|
5.17 |
|
EBITDA (p.s.)
|
-0.57 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
49 (M) |
|
Levered Free Cash Flow
|
59 (M) |
Stock Valuations |
|
PE Ratio
|
571.69 |
|
PEG Ratio
|
-1.8 |
|
Price to Book value
|
15.83 |
|
Price to Sales
|
11.05 |
|
Price to Cash Flow
|
122.69 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
